SCL — Stepan Company · 2026-09-06 · Verdict: PASS · Conviction 3
Price $63.42 (screen row, 2026-09-05 screen; no live quote available) · Mkt cap $1,441.7M · EV $1,975.4M (corrected) · EV/LTM adjusted EBIT ~23x · FCF yield 1.8% (CY2025) · Net debt $533.7M · ADV $6.5M Sources: 10-K 2026-02-26 (Item 7 only; the bundle's split missed Items 1 and 1A), 10-Q 2026-08-05, DEF 14A 2026-03-25, 8-Ks 2026-04-28 and 2026-07-29 with exhibits, Form 4s (22 rows). No transcript in the bundle.
1. What the business actually does
Stepan makes intermediate chemicals across four regions. Surfactants, 73% of first-half 2026 sales, are the active ingredients in detergents, shampoos, disinfectants and agricultural and oilfield products; Polymers, 24%, is polyurethane polyols for rigid insulation foam plus phthalic anhydride and CASE resins; Specialty Products, 3%, is food and pharma emulsifiers (10-Q 2026-08-05). Pricing is largely pass-through: of the 15% second-quarter sales rise, 9 points were price and mix.
2. Why it is mispriced — the edge case
The artifact is real. The first-half $18.5 million net loss "is entirely due to a $70.5 million pre-tax restructuring charge" that cost about $7.0 million of cash year to date, part of Project Catalyst's $75-80 million of charges against $14-18 million of cash, while adjusted EBITDA rose 14% to $124.1 million in the half and 45% to $74.4 million in the quarter (8-K 2026-07-29, EX-99.1).
But nobody is forced to leave it on the table. There is no spin, index deletion or forced seller, and the stock is up 32.4% over twelve months to 3.6% below its 52-week high, from $55.72 at the half end (10-Q). The market paid for the artifact within days.
Worse, the correction runs the wrong way. The screen's EV of $1,572.1M uses only LongTermDebtNoncurrent of $244.1M against $113.7M of cash, while the company's own reconciliation shows net debt of $533.7M on $647.4M of total debt, because $403.3M sits in current maturities (10-Q). True EV is about $1,975M, $403M more than the screen believes.
3. Unit economics and growth
Adjusted EBITDA was $198.9M in 2025 and $187.0M in 2024 on revenue of $2,332.1M (10-K); adding the halves, trailing adjusted EBITDA is $214.1M and the corrected EV is 9.2x. But depreciation matters: D&A was $126.0M in 2025, so trailing adjusted EBIT is roughly $85M, the corrected EV about 23x it, and the return on invested capital near 4% against equity plus net debt of $1,746M.
The inflection is genuine. North American Surfactant gross profit fell $20.0M in 2025 on start-up expense at the new Pasadena, Texas alkoxylation plant and higher oleochemical costs (10-K, Surfactants); it rose $11.0M in the second quarter as those lapped, and North American Polymers volume grew 15%. But management qualified the quarter: "we believe [it] also benefited from customer pre-buys as a result of the global geopolitical situation" (CEO Rojo), and European Polymers volume fell 11% in the half.
Cash conversion is the weak point. 2025 operating cash flow of $147.9M less $122.5M of capex left $25.4M of free cash flow, below the $35.0M of dividends paid (10-K). First-half 2026 free cash flow was negative $29.0M on $77.2M of working capital.
4. Balance sheet and capital allocation
Net debt rose from $494.0M at year end to $533.7M at 30 June, and the credit agreement behind $344M of it matures 24 June 2027, which is why current maturities are $403.3M. Net leverage of about 2.5x sits under a 3.50x covenant, so there is headroom, but the refinancing must happen inside twelve months (10-Q).
No shares were repurchased in 2025 or the first half of 2026 with $125.1M authorised, while the dividend rose for the 58th consecutive year at about $36M a year (8-K 2026-07-29). Across 22 Form 4 rows in twelve months there was not one open-market purchase or sale, only director grants at $52.61. The proxy's own table shows $100 invested at end-2020 worth $43 by end-2025 against $116 for the Dow Jones US Chemicals Index (DEF 14A).
5. Management: what they said vs what they did
April and July carry the identical commitment: "we believe we will deliver full year Adjusted EBITDA growth, positive free cash flow and continue to de-leverage the balance sheet in 2026." The first leg is near automatic, since the first half delivered $124.1M against a full 2025 of $198.9M. The others are not. Positive full-year free cash flow needs a swing from negative $29.0M to better than positive $29.0M, and cutting net debt below $494.0M needs about $28M of second-half free cash flow plus roughly $18M of dividends, close to what the agreed $30 million Millsdale land sale would supply if it closes (8-K 2026-04-28). The promise rests on that sale and a working capital release.
6. Valuation
Base: 2027 adjusted EBITDA of $250M as Catalyst annualises and Pasadena fills, at 8.0x less $500M net debt, about $66. Bear: the pre-buy reverses and Europe stays weak, $200M at 7.0x, about $39. Bull: $290M by 2028 at 8.5x, about $90. Weighted 50/30/20 gives about $63, roughly 1% below price.
Reverse DCF: unlevered free cash flow of roughly $89M (adjusted EBIT $85M taxed at 24%, plus D&A, less $105M guided capex) on the corrected $1,975M EV is a 4.5% yield, so at a 9% cost of capital the price implies about 4.5% perpetual growth from a quarter management says was flattered by pre-buying.
7. Catalysts and timeline
The late-October third quarter, the first clean read on whether the pre-buy reverses; the $30M land sale closing; the June 2027 refinancing; the February 2027 10-K. CEO Rojo's 12,608 performance shares vest only if the stock reaches $100 and $150 for twenty consecutive days by 31 December 2027 (DEF 14A).
8. What would prove this PASS wrong (pre-registered)
- Two consecutive quarters of free cash flow totalling more than $60M, with net debt below $470M.
- An annualised Project Catalyst savings figure above $40M, nowhere quantified here.
- Any open-market insider purchase above $250,000, the first in twelve months.
- Surfactant organic volume growth above 4% for two more quarters, confirming demand rather than pre-buying.
9. Verdict and one-paragraph summary
PASS, conviction 3. Stepan's restructuring artifact is real, the $70.5 million charge behind the first-half loss cost only about $7 million of cash and second-quarter adjusted EBITDA rose 45%, but it is already paid for and the correction runs the wrong way: the screen omitted $403.3 million of current maturities, so true enterprise value is about $1,975 million, not $1,572 million, which is 9.2x trailing adjusted EBITDA but roughly 23x adjusted EBIT once $126 million of annual depreciation is charged against $100-110 million of guided capex. This is a business earning about 4% on invested capital whose 2025 free cash flow of $25.4 million did not cover its $35.0 million dividend and whose first half of 2026 burned $29.0 million, with no forced seller, no insider buying in twelve months, no repurchase in eighteen, and a five-year proxy return of $43 against $116 for its industry index. Its promise of positive full-year free cash flow and de-leveraging leans on a $30 million land sale closing, and a probability-weighted $63 leaves nothing to pay for a June 2027 refinancing.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.